Showing 957 results
-
Press release /Despite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while reference medicines still represent 86% of biologic…
-
Press release /Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) biosimilar offers US patients reduced injection volume in citrate-free formulationAs one of the only adalimumab HCF biosimilars…
-
Press release /The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1Safety in GCA patients was consistent with known safety profile…
-
Press release /Novartis worked with the EMA to update the Beovu® (brolucizumab) label to guide physicians in their treatment of wet AMD The update includes the additional characterization of retinal…
-
Press release /ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after…
-
Press release /Select units of Cosentyx to be made available at 55% discount off list price on direct-to-patient (DTP) platform beginning November 1, 2025DTP offering to expand to other appropriate products;…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment1Well-controlled…
-
Press release /Novartis secured 79.6 percent acceptance by MorphoSys shareholders during the initial acceptance period, reaching the minimum 65% acceptance thresholdSettlement of the shares tendered during the…
-
Press release /Primary results of the Scemblix® ASC4FIRST pivotal Phase III study in first-line Ph+ CML-CP supporting third US FDA Breakthrough Therapy designation, to be detailed in the ASCO Press Program and the…
-
Press release /HER-MES, a Phase IV study, is the first and only randomized, double blind, head-to-head study that compares an antibody targeting the CGRP pathway, Aimovig® (erenumab), with an oral prophylactic…